Nico Scheer is set to join CEVEC Pharmaceuticals GmbH as head of business development for glycoproteins to lead an expansion of the company’s services business. CEVEC produces recombinant glycoproteins and gene therapy vectors for the biopharmaceutical industry. Dr Scheer was previously director of business development at Taconic Biosciences GmbH, another German service provider. He holds a PhD in molecular developmental biology and is a certified project management professional. His appointment will take effect on 1 November.
Simultaneously Hartmut Tintrup, currently the company’s chief business officer, has been appointed vice president business development for gene therapy and viruses.
CEVEC announced the appointments on 14 October 2015.
Copyright 2015 Evernow Publishing Ltd